6533b827fe1ef96bd1285ba3

RESEARCH PRODUCT

Retracted: Do patients profit from physostigmine in recovery from desflurane anaesthesia?

subject

description

Background:  Physostigmine is the drug of choice in the central anticholinergic syndrome, but has also been used in post-operative mental derangement secondary to sedatives and volatile anaesthetics. The aim of this double-blind, randomized, prospective study was to determine whether physostigmine alters recovery after desflurane anaesthesia. Methods:  One hundred patients undergoing urologic or surgical procedures were enrolled to receive either NaCl 0.9% (n= 50) or 2 mg of physostigmine (n= 50) at the end of general anaesthesia with propofol, fentanyl, cisatracurium and desflurane. Times to extubation, stating name, birthday and place of residence, and obeying commands such as eye opening and hand squeezing were noted. Haemodynamics, Aldrete and pain scores, the analgesic requirements, and any adverse side-effects were documented until the 1st post-operative day. Results:  Demographic, peri-operative data including duration of anaesthesia, surgery and postanaesthetic care unit (PACU) stay, and consumption of anaesthetics were comparable in both groups. No significant difference between the groups was found for extubation time or other emergence parameters. Patients undergoing anaesthesia >150 min showed after receiving physostigmine significantly (P 150 min who profit in earlier return to spontaneous breathing and shorter extubation time.